MPR Weekly Dose Podcast Episode 61

This week we cover new findings for the diabetes drug sitagliptin in pediatrics; An obesity treatment has its approval expanded; The FDA issue a Complete Response Letter for an outpatient alternative treatment; And news of availability for a transdermal contraceptive patch.

Saxenda Approved for Obesity in Adolescent Patients

The FDA has approved Saxenda® (liraglutide; Novo Nordisk) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients aged 12 years and older with body weight >60kg and an initial BMI corresponding to ≥30kg/m2 for adults (obese).